SLC5A2 and colorectal neoplasm: Our study provides the first comprehensive NMA addressing the incidence of colorectal tumors related to individual GLP-1 receptor agonists and SGLT2 inhibitors, suggesting a dose–dependent relationship to semaglutide, particularly in its high-dose injectable form (2.4 mg/week).